{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:45:09Z","timestamp":1792651509322,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Gates Foundation","doi-asserted-by":"publisher","award":["INV007838"],"award-info":[{"award-number":["INV007838"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.vaccine.2025.128186","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T19:10:12Z","timestamp":1767726612000},"page":"128186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Determining the dose-response relationship for pneumococcal conjugate vaccines: a nested analysis of the fractional dose PCV trial"],"prefix":"10.1016","volume":"73","author":[{"given":"Irene","family":"Martinez-de-Albeniz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Bottomley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Lucinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Wanjiru","family":"Kaniu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suaad","family":"Badaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Mutahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mwalekwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ragab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Twi-Yeboah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Berkley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mainga","family":"Hamaluba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Karani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Shangala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Otiende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Gardiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Mugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collins","family":"Tabu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Were","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Goldblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Anthony G.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10369","key":"10.1016\/j.vaccine.2025.128186_bb0005","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/S0140-6736(22)02185-7","article-title":"Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the global burden of disease study 2019","volume":"400","author":"Collaborators","year":"2022","journal-title":"Lancet"},{"issue":"10186","key":"10.1016\/j.vaccine.2025.128186_bb0010","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/S0140-6736(18)33005-8","article-title":"Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study","volume":"393","author":"Hammitt","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.vaccine.2025.128186_bb0015","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.3201\/eid2111.140780","article-title":"Invasive pneumococcal disease 3 years after introduction of 10-valent pneumococcal conjugate vaccine, the Netherlands","volume":"21","author":"Knol","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2025.128186_bb0020","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.13.05002","article-title":"Systematic review on the impact of the pneumococcal conjugate vaccine ten valent (PCV10) or thirteen valent (PCV13) on all-cause, radiologically confirmed and severe pneumonia hospitalisation rates and pneumonia mortality in children 0-9 years old","volume":"13","author":"Reyburn","year":"2023","journal-title":"J Glob Health"},{"issue":"6","key":"10.1016\/j.vaccine.2025.128186_bb0025","first-page":"629","article-title":"Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study","volume":"15","author":"Waight","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2025.128186_bb0030","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1469-0691.2010.03183.x","article-title":"Streptococcus pneumoniae: virulence factors and variation","volume":"16","author":"Mitchell","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2025.128186_bb0035","unstructured":"International Vaccine Access Center (IVAC) JHBSoPH. Pneumococcal conjugate vaccines (PCV). VIEW-hub, 2025. Available from: https:\/\/view-hub.org\/vaccine\/pcv. Accessed 20\/12\/2025."},{"issue":"2","key":"10.1016\/j.vaccine.2025.128186_bb0040","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2025.128186_bb0045","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00006454-200003000-00003","article-title":"Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente vaccine study center group","volume":"19","author":"Black","year":"2000","journal-title":"Pediatr Infect Dis J"},{"issue":"9381","key":"10.1016\/j.vaccine.2025.128186_bb0050","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(03)14022-6","article-title":"Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial","volume":"362","author":"O\u2019Brien","year":"2003","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.vaccine.2025.128186_bb0055","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMoa035060","article-title":"A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection","volume":"349","author":"Klugman","year":"2003","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.vaccine.2025.128186_bb0060","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1016\/j.vaccine.2007.01.119","article-title":"Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies","volume":"25","author":"Siber","year":"2007","journal-title":"Vaccine"},{"issue":"23","key":"10.1016\/j.vaccine.2025.128186_bb0065","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1016\/S0264-410X(03)00230-5","article-title":"Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants","volume":"21","author":"Jodar","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.128186_bb0070","series-title":"World Health Organization. Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines.","year":"2013"},{"key":"10.1016\/j.vaccine.2025.128186_bb0075","series-title":"Product monograph: Synflorix. Pneumococcal conjugate vaccine (non-Typeable Haemophilus influenzae (NTHi) protein D, diphtheria or tetanus toxoid conjugates) adsorbed","year":"2024"},{"issue":"2","key":"10.1016\/j.vaccine.2025.128186_bb0085","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00084-18","article-title":"Factors that influence the immune response to vaccination","volume":"32","author":"Zimmermann","year":"2019","journal-title":"Clin Microbiol Rev"},{"issue":"31","key":"10.1016\/j.vaccine.2025.128186_bb0090","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1016\/j.vaccine.2011.04.053","article-title":"Comparative effects of carrier proteins on vaccine-induced immune response","volume":"29","author":"Knuf","year":"2011","journal-title":"Vaccine"},{"issue":"34","key":"10.1016\/j.vaccine.2025.128186_bb0095","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1016\/j.vaccine.2010.06.026","article-title":"Glycoconjugate vaccines and immune interference: a review","volume":"28","author":"Dagan","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.128186_bb0100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jtbi.2019.01.017","article-title":"Dose finding for new vaccines: the role for immunostimulation\/immunodynamic modelling","volume":"465","author":"Rhodes","year":"2019","journal-title":"J Theor Biol"},{"issue":"50","key":"10.1016\/j.vaccine.2025.128186_bb0105","doi-asserted-by":"crossref","first-page":"6285","DOI":"10.1016\/j.vaccine.2016.10.060","article-title":"The TB vaccine H56+IC31 dose-response curve is peaked not saturating: data generation for new mathematical modelling methods to inform vaccine dose decisions","volume":"34","author":"Rhodes","year":"2016","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2025.128186_bb0110","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/infdis\/jiw237","article-title":"Fractional Third and Fourth Dose of RTS,S\/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study","volume":"214","author":"Regules","year":"2016","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2025.128186_bb0115","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1097\/INF.0b013e31824b9545","article-title":"Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic a\/H1N1 influenza vaccine in children 3 to < 9 years of age","volume":"31","author":"Nassim","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"36","key":"10.1016\/j.vaccine.2025.128186_bb0120","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.1016\/j.vaccine.2021.07.033","article-title":"Pneumococcal conjugate vaccine dose-ranging studies in humans: a systematic review","volume":"39","author":"Lucinde","year":"2021","journal-title":"Vaccine"},{"issue":"21","key":"10.1016\/j.vaccine.2025.128186_bb0125","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1056\/NEJMoa2314620","article-title":"Fractional doses of pneumococcal conjugate vaccine - a noninferiority trial","volume":"391","author":"Gallagher","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.128186_bb0130","unstructured":"Nahm M.G.D., Goldblatt D. World Health Organization Pneumococcal Serology Reference Laboratories. Training manual for enzyme linked immunosorbent assay for the quantitation of Streptococcus pneumoniae serotype specific IgG (PnPg ELISA). 2024. Available from: https:\/\/www.vaccine.uab.edu\/uploads\/mdocs\/ELISAProtocol(007sp).pdf."},{"issue":"14","key":"10.1016\/j.vaccine.2025.128186_bb0135","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.vaccine.2016.02.036","article-title":"Sex-dependent immune responses to infant vaccination: an individual participant data meta-analysis of antibody and memory B cells","volume":"34","author":"Voysey","year":"2016","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2025.128186_bb0140","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jamapediatrics.2017.0638","article-title":"The influence of maternally derived antibody and infant age at vaccination on infant vaccine responses\u202f: an individual participant Meta-analysis","volume":"171","author":"Voysey","year":"2017","journal-title":"JAMA Pediatr"},{"issue":"3","key":"10.1016\/j.vaccine.2025.128186_bb0145","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jpeds.2003.11.030","article-title":"Effect of maternal antibody on immunogenicity of hepatitis a vaccine in infants","volume":"144","author":"Letson","year":"2004","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2025.128186_bb0150","doi-asserted-by":"crossref","unstructured":"Park DE, Johnson TS, Nonyane BA, Chandir S, Conklin L, Fleming-Dutra KE, et al. The differential impact of coadministered vaccines, geographic region, vaccine product and other covariates on pneumococcal conjugate vaccine immunogenicity. Pediatr Infect Dis J. 2014;33 Suppl 2(Suppl 2 Optimum Dosing of Pneumococcal Conjugate Vaccine For Infants 0 A Landscape Analysis of Evidence Supportin g Different Schedules):S130\u20139.","DOI":"10.1097\/INF.0000000000000081"},{"issue":"4","key":"10.1016\/j.vaccine.2025.128186_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001017","article-title":"Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study","volume":"8","author":"Flasche","year":"2011","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128186_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079578","article-title":"Nasopharyngeal carriage and transmission of Streptococcus pneumoniae in American Indian households after a decade of pneumococcal conjugate vaccine use","volume":"9","author":"Mosser","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.vaccine.2025.128186_bb0165","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1136\/adc.88.3.211","article-title":"Pneumococcal nasopharyngeal carriage in children following heptavalent pneumococcal conjugate vaccination in infancy","volume":"88","author":"Lakshman","year":"2003","journal-title":"Arch Dis Child"},{"issue":"6","key":"10.1016\/j.vaccine.2025.128186_bb0170","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/cid\/cix895","article-title":"Serotype-specific correlates of protection for pneumococcal carriage: an analysis of immunity in 19 countries","volume":"66","author":"Voysey","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2025.128186_bb0175","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1473-3099(14)70822-9","article-title":"Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study","volume":"14","author":"Andrews","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2025.128186_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9040696","article-title":"Changes in invasive pneumococcal disease caused by Streptococcus pneumoniae serotype 1 following introduction of PCV10 and PCV13: findings from the PSERENADE project","volume":"9","author":"Bennett","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.vaccine.2025.128186_bb0185","article-title":"Serotype distribution by age of remaining invasive pneumococcal disease after long-term PCV10\/13 use: the PSERENADE project","volume":"8","author":"Garcia Quesada","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2025.128186_bb0190","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1473-3099(24)00588-7","article-title":"Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysis","volume":"25","author":"Garcia Quesada","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128186_bb0195","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1038\/s41467-020-15786-9","article-title":"High residual carriage of vaccine-serotype Streptococcus pneumoniae after introduction of pneumococcal conjugate vaccine in Malawi","volume":"11","author":"Swarthout","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2025.128186_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijid.2021.11.021","article-title":"Pneumococcal carriage among children in low and lower-middle-income countries: a systematic review","volume":"115","author":"Tvedskov","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2025.128186_bb0205","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jpeds.2010.04.071","article-title":"Serotype-specific hyporesponsiveness to pneumococcal conjugate vaccine in infants carrying pneumococcus at the time of vaccination","volume":"157","author":"Vakevainen","year":"2010","journal-title":"J Pediatr"},{"issue":"10","key":"10.1016\/j.vaccine.2025.128186_bb0210","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1086\/652006","article-title":"Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy","volume":"201","author":"Dagan","year":"2010","journal-title":"J Infect Dis"},{"issue":"35 Pt B","key":"10.1016\/j.vaccine.2025.128186_bb0215","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1016\/j.vaccine.2017.05.088","article-title":"Pneumococcal conjugate vaccine induced IgG and nasopharyngeal carriage of pneumococci: Hyporesponsiveness and immune correlates of protection for carriage","volume":"35","author":"Ojal","year":"2017","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25014847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25014847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T09:05:05Z","timestamp":1770282305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25014847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":42,"alternative-id":["S0264410X25014847"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.128186","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determining the dose-response relationship for pneumococcal conjugate vaccines: a nested analysis of the fractional dose PCV trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.128186","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128186"}}